Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.72 |
| ▸ | THRA | P10827 | 17/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13381699 | 0.92 | THRB (0.61) | THRBTHRAPTPN1NUDT1BACE1 | |
| SCHEMBL10274395 | 0.84 | THRB (1.00) | THRBTHRAPTPN1 | |
| SCHEMBL3159629 | 0.84 | THRB (0.56) | THRBTHRAPTPN1 | |
| SCHEMBL328296 | 0.81 | THRB (0.76) | THRBTHRAPTPN1 | |
| SCHEMBL328325 | 0.81 | THRB (1.00) | THRBTHRAPTPN1BACE1 | |
| SCHEMBL282128 | 0.81 | THRB (0.79) | THRBTHRAPTPN1 | |
| SCHEMBL282663 | 0.79 | THRB (0.76) | THRBTHRAPTPN1 | |
| Mb07344 SCHEMBL282003 | 0.79 | THRB (1.00) | THRBTHRA | |
| SCHEMBL21565925 | 0.79 | THRB (0.76) | THRBTHRAPTPN1 | |
| SCHEMBL283361 | 0.79 | THRB (0.76) | THRBTHRAPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707472-B2 | Compositions for the treatment of fibrosis | VIKING THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20220016137-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. | 2022-01-20 | — | — | US | disclosed |
| US-11202789-B2 | Method of treating glycogen storage disease | VIKING THERAPEUTICS, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | METABASIS THERAPEUTICS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | VIKING THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| WO-2020117987-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | VIKING THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1689383-A4 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| EP-1891080-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006128055-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| EP-1689383-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | Metabasis Therapeutics, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2005051298-A2 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS, INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016136-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, TSHR | THRB 7/4885THRA 8/4885PTPN1 555/4885 |
| US-10925885-B2 | Thyromimetics for the treatment of fatty liver diseases | TSHR, THRA, FABP1 | THRB 4/4885THRA 2/4885PTPN1 721/4885 |
| US-20220016137-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS AND INFLAMMATION | COL2A1, COL1A1, TGFBR2 | THRB 30/4885THRA 187/4885PTPN1 2080/4885 |
| US-11707472-B2 | Compositions for the treatment of fibrosis | COL2A1, TGFBR2, COL1A1 | THRB 33/4885THRA 251/4885PTPN1 2244/4885 |
| US-20200179412-A1 | COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | COL2A1, TGFBR2, COL1A1 | THRB 33/4885THRA 251/4885PTPN1 2244/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | THRB 6/4885THRA 2/4885PTPN1 70/4885 |
| US-11202789-B2 | Method of treating glycogen storage disease | GYS2, GYS1, PYGL | THRB 7/4885THRA 9/4885PTPN1 1314/4885 |
| US-20230226038-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS | FABP1, SLC10A1, LIPC | THRB 19/4885THRA 25/4885PTPN1 671/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | THRB 41/4885THRA 14/4885PTPN1 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.